Cassava Sciences (NYSE: SAVA) — Perfil da empresa, notícias e dados financeiros
Cassava Sciences develops drugs for neurodegenerative diseases including Alzheimer's, focusing on innovative treatments.
Cassava Sciences
Cassava Sciences (NASDAQ:SAVA) focuses primarily on the discovery and development of drugs for neurodegenerative diseases, including Alzheimer's disease. The company's innovative approach includes simufilam, its lead drug candidate designed to treat Alzheimer's by restoring the normal shape and function of a key brain protein. Additionally, Cassava is working on an early detection blood test for Alzheimer's, aiming to identify the disease in its nascent stages. With a commitment to advancing Alzheimer's research and providing new hope for patients and families affected by this condition, Cassava Sciences is dedicated to improving outcomes in the field of neurology.
Resumo
Operações
Produtos e/ou serviços de Cassava Sciences
- Simufilam, a novel drug targeting the treatment of Alzheimer's disease by restoring normal protein shape.
- PTI-125, which focuses on reducing neuroinflammation and improving cognitive function.
- Cognitive assessment tests developed to effectively evaluate the progression and symptoms of Alzheimer's.
- Research collaborations aimed at advancing understanding of Alzheimer's pathology and potential therapeutic targets.
- Outreach and educational programs dedicated to raising awareness and understanding of Alzheimer's disease among patients, caregivers, and healthcare professionals.
equipe executiva do Cassava Sciences
- Mr. Richard Jon BarryCEO, President & Director
- Mr. Eric J. SchoenChief Financial Officer
- Mr. R. Christopher Cook J.D.Chief Operating & Legal Officer
- Dr. George Thornton Ph.D.Senior Vice President of Technology
- Mr. Michael ZamlootSenior Vice President of Technical Operations
- Ms. Freda NassifChief Business Officer & Chief Commercial Officer
- Jaren LandenChief Clinical Development Officer
- Dr. Angélique Bordey Ph.D.Senior Vice President of Neuroscience
- Mr. Jack Moore Ph.D.Senior Vice President of Clinical Development
- Dr. Joseph Hulihan M.D.Chief Medical Officer
Principais indicadores financeiros
Resultados divulgados pela Cassava Sciences, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -95,4 mi | -91 mi | |
| 0 | -141,4 mi | -24,3 mi | |
| 0 | -106 mi | -97,2 mi | |
| -1,8 mil | -80 mi | -72,5 mi |